Entrada Therapeutics, Inc. (NASDAQ:TRDA) Shares Bought by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 34.7% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 14,156 shares of the company’s stock after purchasing an additional 3,644 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Entrada Therapeutics were worth $226,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Connor Clark & Lunn Investment Management Ltd. lifted its stake in shares of Entrada Therapeutics by 132.4% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 138,605 shares of the company’s stock worth $2,215,000 after buying an additional 78,953 shares during the period. Massachusetts Financial Services Co. MA purchased a new position in Entrada Therapeutics in the 3rd quarter worth $1,109,000. Renaissance Technologies LLC acquired a new stake in Entrada Therapeutics during the 2nd quarter worth about $636,000. Los Angeles Capital Management LLC purchased a new stake in Entrada Therapeutics during the 3rd quarter valued at about $542,000. Finally, BayBridge Capital Group LLC acquired a new position in shares of Entrada Therapeutics in the third quarter valued at about $464,000. Institutional investors and hedge funds own 86.39% of the company’s stock.

Insider Buying and Selling

In other Entrada Therapeutics news, CFO Kory James Wentworth sold 5,000 shares of the firm’s stock in a transaction that occurred on Monday, December 2nd. The stock was sold at an average price of $20.00, for a total value of $100,000.00. Following the sale, the chief financial officer now directly owns 73,849 shares of the company’s stock, valued at approximately $1,476,980. This trade represents a 6.34 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, major shareholder Bioventures 2018 L.P. Mpm sold 22,935 shares of the business’s stock in a transaction that occurred on Tuesday, December 10th. The shares were sold at an average price of $20.77, for a total value of $476,359.95. Following the completion of the sale, the insider now owns 4,402,849 shares of the company’s stock, valued at $91,447,173.73. This trade represents a 0.52 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,128 shares of company stock valued at $875,551. Corporate insiders own 7.59% of the company’s stock.

Wall Street Analysts Forecast Growth

TRDA has been the subject of a number of research reports. Roth Capital raised Entrada Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Roth Mkm began coverage on shares of Entrada Therapeutics in a research note on Thursday, December 5th. They issued a “buy” rating and a $29.00 price objective on the stock. HC Wainwright boosted their target price on shares of Entrada Therapeutics from $18.00 to $20.00 and gave the company a “buy” rating in a research report on Wednesday, November 6th. Finally, Oppenheimer upped their price target on shares of Entrada Therapeutics from $25.00 to $28.00 and gave the company an “outperform” rating in a report on Wednesday, November 6th.

Entrada Therapeutics Price Performance

Shares of NASDAQ TRDA opened at $17.59 on Friday. The stock has a market capitalization of $658.22 million, a price-to-earnings ratio of 11.06 and a beta of -0.18. The firm’s 50 day simple moving average is $18.54 and its 200-day simple moving average is $16.70. Entrada Therapeutics, Inc. has a 12 month low of $11.35 and a 12 month high of $21.79.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.